A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome

1 2 3 4 5 6 7 8 9 10 11 12 13 14 Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer

for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.7112.

Fagotti A, Vizzielli G, De Iaco P, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of

laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013;209(5):462.e1–462.

e11. doi:10.1016/j.ajog.2013.07.016.

Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9(3):297–303.

doi:10.1016/S1470-2045(08)70074-3.

Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian

Cancer. N Engl J Med. 2019;381(25):2416–2428. doi:10.1056/NEJMoa1911361.

He XQ, Gao YT, Zhang X, Jiang H. Time Intervals between Double Primary Breast and Ovarian Cancers

and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis. Biomed Res Int.

2022;2022:4557346. doi:10.1155/2022/4557346.

Tasca G, Dieci MV, Baretta Z, et al. Synchronous and Metachronous Breast and Ovarian Cancer: Experience

From Two Large Cancer Center. Front Oncol. 2020;10:608783. doi:10.3389/fonc.2020.608783.

Dilawari A, Cangiarella J, Smith J, Huang A, Downey A, Muggia F. Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. Ecancermedicalscience. 2008;2:109. doi:10.3332/ecancer.2008.109.

Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G. Invasive bilateral breast cancer and high

grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.

Arch Clin Cases. 2021;6(3):69–75. doi:10.22551/2019.24.0603.10156.

Chan GHJ, Ong PY, Low JJH, et al. Clinical genetic testing outcome with multi-gene panel in Asian

patients with multiple primary cancers. Oncotarget. 2018;9(55):30649–30660. doi:10.18632/oncotarget.25769.

Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM,

Gallón-Villegas LJ. Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A

Case Report. Case Rep Oncol Med. 2019;2019:6958952. doi:10.1155/2019/6958952.

Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol.

1994;84(3):449–452.

Moore EK, Roylance R, Rosenthal AN. Breast cancer metastasising to the pelvis and abdomen: what the

gynaecologist needs to know. BJOG. 2012;119(7):788–794. doi:10.1111/j.1471-0528.2012.03314.x.

Rutten MJ, van Meurs HS, van de Vrie R, et al. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial. J Clin Oncol.

2017;35(6):613–621. doi:10.1200/JCO.2016.69.2962.

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant

Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi:10.1200/

Nagoya J. Med. Sci. 85. 814–821, 2023

820

doi:10.18999/nagjms.85.4.814

Simultaneous cancers due to HBOC

JCO.2007.15.0235.

Xia LY, Hu QL, Zhang J, Xu WY, Li XS. Survival outcomes of neoadjuvant versus adjuvant chemotherapy

in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol. 2020;18(1):129.

doi:10.1186/s12957-020-01907-7.

16 Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed

advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet.

2015;386(9990):249–257. doi:10.1016/S0140-6736(14)62223-6.

17 Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated

Breast Cancer. N Engl J Med. 2021;384(25):2394–2405. doi:10.1056/NEJMoa2105215.

18 Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced

Ovarian Cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858.

19 Yu KD, Ye FG, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With

Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1390–1396.

doi:10.1001/jamaoncol.2020.2965.

20 Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients

with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13(8):1156–1161. doi:10.1245/

ASO.2006.08.021.

References End

15 Nagoya J. Med. Sci. 85. 814–821, 2023

821

doi:10.18999/nagjms.85.4.814

...